PRF Technologies Ltd. (PRFX)
PRFX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1801834/000117891326001782/0001178913-26-001782-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRFX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2020 |
| SEC CIK | 0001801834 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17K |
| Net income | -$5.0M |
| Operating income | -$5.1M |
| Net margin | -29541.2% |
| Operating margin | -30129.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $3.1M |
| Total assets | $12.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 143.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Therefore, there is substantial doubt about our ability to continue as a going concern." | 20-F 2026-03-26 |
| Cash and burn | $3.1M cash; operating cash flow -$989K a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-5 on 2026-02-06 | Source 2026-02-06 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-04-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $17K | -$5.0M | -$4.0M | $3.1M | No debt tags | $17K | 20-F 2026-03-26 |
| FY 2024 2024-12-31 | $0 | -$14.6M | -$12.6M | $4.3M | No debt tags | $0 | 20-F 2026-03-26 |
| FY 2023 2023-12-31 | $0 | -$9.3M | -$6.7M | $8.0M | No debt tags | $0 | 20-F 2026-03-26 |
| FY 2022 2022-12-31 | Not filed | -$8.8M | -$6.5M | $4.1M | No debt tags | Needs four quarters | 20-F 2025-04-07 |
| FY 2021 2021-12-31 | Not filed | -$7.2M | -$6.6M | $16.5M | No debt tags | Needs four quarters | 20-F 2024-02-29 |
| FY 2020 2020-12-31 | Not filed | -$4.1M | -$2.6M | $15.7M | No debt tags | Needs four quarters | 20-F 2023-03-15 |
| FY 2019 2019-12-31 | Not filed | -$1.3M | -$609K | $941K | $14.5M | Needs four quarters | 20-F 2022-03-16 |
| FY 2018 2018-12-31 | Not filed | -$828K | -$635K | $46K | $3.7M | Needs four quarters | 20-F 2021-03-18 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-09-03 |
| Latest annual report | 20-F | 2026-03-26 |
| Latest quarterly / interim | 6-K | 2026-11-13 |
Source: SEC EDGAR submissions feed, 265 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.1% |
| 1 month | -4.3% |
| 3 months | -34.7% |
| Year to date | -75.6% |
| 1 year | -83.2% |
| From 52-week high | -86.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GNPX | Genprex Inc. | $1.90 | -8.65% | $2.5M |
| REVB | Revelation Biosciences Inc. | $3.82 | -10.43% | $2.6M |
| EOCN | Eocene Ltd. | $2.53 | +5.86% | $2.6M |
| JUNS | Jupiter Neurosciences Inc. | $1.70 | -8.11% | $2.2M |
| PPBT | Purple Biotech Ltd. | $1.68 | +3.70% | $2.7M |
| DCOY | Decoy Therapeutics Inc. | $0.9010 | -7.61% | $2.1M |
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier